Riverbridge Partners LLC acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 105,599 shares of the medical instruments supplier’s stock, valued at approximately $11,528,000.
Other hedge funds have also recently made changes to their positions in the company. Illinois Municipal Retirement Fund raised its holdings in shares of LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after acquiring an additional 123 shares in the last quarter. NewEdge Advisors LLC increased its position in LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the period. State of Alaska Department of Revenue increased its position in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the period. Federated Hermes Inc. raised its holdings in LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after purchasing an additional 155 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 32.7% in the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 179 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.
LeMaitre Vascular Stock Performance
Shares of LMAT stock opened at $91.95 on Wednesday. The company’s fifty day moving average price is $101.48 and its 200-day moving average price is $96.53. The stock has a market cap of $2.10 billion, a PE ratio of 33.93, a price-to-earnings-growth ratio of 2.46 and a beta of 0.54. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 12 month low of $79.00 and a 12 month high of $118.01.
LeMaitre Vascular Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.1%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on LMAT. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Barrington Research restated an “outperform” rating and issued a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. Finally, Roth Mkm reiterated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.
Read Our Latest Stock Analysis on LMAT
Insider Activity
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 54,453 shares of company stock worth $5,906,174. Insiders own 7.40% of the company’s stock.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
